The 36-month beta value for LUNG is at 0.49. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for LUNG is 34.61M, and currently, shorts hold a 3.32% of that float. The average trading volume for LUNG on March 06, 2025 was 317.64K shares.
LUNG) stock’s latest price update
Pulmonx Corp (NASDAQ: LUNG)’s stock price has plunge by -5.54relation to previous closing price of 8.67. Nevertheless, the company has seen a -11.17% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-03 that PDF Version LYON, France, March 3, 2025 — EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors. “We are pleased to welcome Glen to our Board of Directors,” said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS.
LUNG’s Market Performance
Pulmonx Corp (LUNG) has seen a -11.17% fall in stock performance for the week, with a 40.24% gain in the past month and a 26.98% surge in the past quarter. The volatility ratio for the week is 11.30%, and the volatility levels for the past 30 days are at 8.59% for LUNG. The simple moving average for the past 20 days is 5.91% for LUNG’s stock, with a 17.79% simple moving average for the past 200 days.
Analysts’ Opinion of LUNG
Many brokerage firms have already submitted their reports for LUNG stocks, with Citigroup repeating the rating for LUNG by listing it as a “Neutral.” The predicted price for LUNG in the upcoming period, according to Citigroup is $7.50 based on the research report published on December 11, 2024 of the previous year 2024.
Lake Street, on the other hand, stated in their research note that they expect to see LUNG reach a price target of $12. The rating they have provided for LUNG stocks is “Buy” according to the report published on June 04th, 2024.
Wells Fargo gave a rating of “Equal Weight” to LUNG, setting the target price at $14 in the report published on February 23rd of the previous year.
LUNG Trading at 18.79% from the 50-Day Moving Average
After a stumble in the market that brought LUNG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.18% of loss for the given period.
Volatility was left at 8.59%, however, over the last 30 days, the volatility rate increased by 11.30%, as shares surge +41.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.26% upper at present.
During the last 5 trading sessions, LUNG fell by -11.17%, which changed the moving average for the period of 200-days by -12.12% in comparison to the 20-day moving average, which settled at $7.73. In addition, Pulmonx Corp saw 20.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LUNG starting from Joshi Mehul, who sale 14,384 shares at the price of $7.12 back on Mar 03 ’25. After this action, Joshi Mehul now owns 113,986 shares of Pulmonx Corp, valued at $102,414 using the latest closing price.
Williamson Steven S., the PRESIDENT AND CEO of Pulmonx Corp, sale 27,689 shares at $7.14 during a trade that took place back on Mar 03 ’25, which means that Williamson Steven S. is holding 194,342 shares at $197,699 based on the most recent closing price.
Stock Fundamentals for LUNG
Current profitability levels for the company are sitting at:
- -0.69 for the present operating margin
- 0.74 for the gross margin
The net margin for Pulmonx Corp stands at -0.67. The total capital return value is set at -0.42. Equity return is now at value -55.25, with -32.54 for asset returns.
Based on Pulmonx Corp (LUNG), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at -0.56. The debt to equity ratio resting at 0.66. The interest coverage ratio of the stock is -16.45.
Currently, EBITDA for the company is -57.7 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 3.72. The receivables turnover for the company is 6.08for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.58.
Conclusion
In conclusion, Pulmonx Corp (LUNG) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
